½ÃÀ庸°í¼­
»óǰÄÚµå
1620815

Áã ¹× ¸¶¿ì½º ¸ðµ¨ ½ÃÀå : ¸ðµ¨ À¯Çü, ±â¼ú, ¼­ºñ½º, Ä¡·á ¿µ¿ª, ÃÖÁ¾ »ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Rat & Mouse Model Market by Model Type, Technology, Service, Therapeutic Area, End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 183 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Áã ¹× ¸¶¿ì½º ¸ðµ¨ ½ÃÀåÀÇ 2023³â ½ÃÀå ±Ô¸ð´Â 22¾ï 7,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 24¾ï 5,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 8.26%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 39¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Áã ¹× ¸¶¿ì½º ¸ðµ¨ ½ÃÀåÀº »ý¹° ÀÇÇÐ ¿¬±¸¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, ¼³Ä¡·ù¿Í Àΰ£ÀÇ À¯ÀüÀû, »ý¹°ÇÐÀû À¯»ç¼ºÀ¸·Î ÀÎÇØ Àΰ£ Áúº´ ¸ÞÄ¿´ÏÁò¿¡ ´ëÇÑ ±ÍÁßÇÑ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¸ðµ¨Àº Áúº´ ÁøÇà, ¾à¹° »óÈ£ÀÛ¿ë, À¯ÀüÀÚ ¹ßÇö ¿¬±¸¿¡ ÇʼöÀûÀ̸ç, Á¦¾à ¹× »ý¸í°øÇÐ »ê¾÷ÀÇ ÀüÀÓ»ó½ÃÇè¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀÀ¿ë ¹üÀ§´Â Á¾¾çÇÐ, ½ÉÀ庴ÇÐ, ½Å°æ°úÇÐ, ¸é¿ªÇÐ, À¯ÀüÇÐ ¿¬±¸¿¡ À̸£±â±îÁö ´Ù¾çÇϸç, ÃÖÁ¾ »ç¿ëÀÚ´Â ¿¬±¸±â°ü, Á¦¾àȸ»ç, À§Å¹¿¬±¸±â°ü µîÀ» Æ÷ÇÔÇÕ´Ï´Ù. ÇöÀç ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº À¯Àü°øÇÐ ±â¼úÀÇ ¹ßÀü, R&D ÅõÀÚ Áõ°¡, Çõ½ÅÀûÀÎ Ä¡·á¹ýÀ» ÇÊ¿ä·Î ÇÏ´Â ¸¸¼º Áúȯ Áõ°¡ÀÔ´Ï´Ù. °³ÀθÂÃãÇü ÀÇ·á¿¡ °³¹ß ±âȸ°¡ ÀÖÀ¸¸ç, ¸¶¿ì½º ¸ðµ¨À» ¸ÂÃãÈ­ÇÏ¿© Ç¥ÀûÄ¡·áÁ¦ °³¹ßÀ» °¡¼ÓÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ CRISPR-Cas9 ±â¼úÀÇ ºÎ»ó°ú À¯ÀüÀÚ Á¶ÀÛÀ» ÅëÇÑ Àΰ£È­ ¸¶¿ì½º ¸ðµ¨ÀÇ »ç¿ë È®´ë´Â ¿¬±¸ ¿ª·®À» È®ÀåÇϰí À¯¸®ÇÑ ¼ºÀå °æ·Î¸¦ Á¦°øÇÕ´Ï´Ù. ±×·¯³ª µ¿¹° ½ÇÇè¿¡ ´ëÇÑ À±¸®Àû ¹®Á¦, ±ÔÁ¦ ¹®Á¦, ´ëü ü¿Ü ¹× ü¿Ü ¸ðµ¨·ÎÀÇ ÀüȯÀ¸·Î ÀÎÇØ ½ÃÀå È®´ë°¡ Á¦Çѵǰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »ì¾ÆÀÖ´Â µ¿¹° ±ºÁý À¯Áö¿¡ µû¸¥ º¹À⼺°ú ºñ¿ëµµ Å« Á¦¾àÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±âȸ¸¦ Ȱ¿ëÇϱâ À§ÇØ ÀÌÇØ°ü°èÀÚµéÀº AI¿Í ¸Ó½Å·¯´×À» ÅëÇÕÇÏ¿© µ¿¹° ½ÇÇè µ¥ÀÌÅÍ ºÐ¼®ÀÇ È¿À²¼ºÀ» ³ôÀÌ´Â µ¥ ÁýÁßÇØ¾ß ÇÕ´Ï´Ù. °ß°íÇÑ ½ÃÇè°ü ³» ½Ã¹Ä·¹ÀÌ¼Ç ±â¼úÀÇ °³¹ßÀº ±âÁ¸ÀÇ µ¿¹° ¸ðµ¨À» º¸¿ÏÇÏ°í ´ëüÇÒ ¼ö ÀÖÀ¸¸ç, º¯È­ÇÏ´Â ±ÔÁ¦ ¹× À±¸®Àû ±âÁØ¿¡ ºÎÇÕÇÒ ¼ö ÀÖ½À´Ï´Ù. Çõ½ÅÀº ¶ÇÇÑ ¸ðµ¨ÀÇ Á¤È®¼º°ú °ü·Ã¼ºÀ» Çâ»ó½Ã۱â À§ÇØ À¯ÀüÀÚ Á¶ÀÛ ÀýÂ÷ÀÇ °³¼±¿¡ ÃÊÁ¡À» ¸ÂÃß¾î¾ß ÇÕ´Ï´Ù. ÇöÀç Áã-Á㠸𵨠½ÃÀåÀº °ßÁ¶ÇÑ ¼ö¿ä Àü¸Á°ú ±â¼ú ¹ßÀü ¹× À±¸®Àû °üÁ¡ÀÇ º¯È­·Î ÀÎÇØ ¿ªµ¿ÀûÀÎ ¹Ì·¡¸¦ ¸ÂÀÌÇϰí ÀÖÀ¸¸ç, ÀÌ ºÐ¾ßÀÇ ±â¾÷µéÀº ÀûÀÀ Àü·«À» ÇÊ¿ä·Î Çϰí ÀÖ½À´Ï´Ù. Áö¼ÓÀûÀÎ Çõ½Å°ú Àü·«Àû ÀûÀÀÀ» ÅëÇØ ÀÌ ½ÃÀåÀº Å« ¼ºÀå ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 22¾ï 7,000¸¸ ´Þ·¯
ÃßÁ¤³â(2024) 24¾ï 5,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 39¾ï 7,000¸¸ ´Þ·¯
CAGR(%) 8.26%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â Áã-Á㠸𵨠½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

Áã¿Í ¸¶¿ì½º ¸ðµ¨ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Ä¡·á Ç¥Àû °ËÁõÀ» À§ÇÑ À¯ÀüÀÚ ÀçÁ¶ÇÕ ¸ðµ¨¿¡ ´ëÇÑ Å« ¼ö¿ä
    • Á¦¾à ¹× »ý¸í°øÇÐ ºÐ¾ß R&D ºñ¿ë Áõ°¡
    • °³ÀθÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä ±ÞÁõ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • À±¸®Àû ¿ì·Á¿Í Áã-¸¶¿ì½º ¸ðµ¨ÀÇ ÇѰè
  • ½ÃÀå ±âȸ
    • Àΰ£È­ Áã-¸¶¿ì½º ¸ðµ¨·ÎÀÇ Àüȯ
    • ¼ºÀåÇÏ´Â Ä¡·á ¿¬±¸ ºÐ¾ß
  • ½ÃÀå °úÁ¦
    • ´ëü °Ë»ç ¹æ¹ýÀÇ Á¸Àç

Porter's Five Forces: Áã-¸¶¿ì½º ¸ðµ¨ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÆÄ¾ÇÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. PorterÀÇ Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Áã-Á㠸𵨠½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

PESTLE ºÐ¼® : Áã-Á㠸𵨠½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Á㠸𵨠½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® Áã-¸¶¿ì½º ¸ðµ¨ ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

Áã ¹× ¸¶¿ì½º ¸ðµ¨ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ º¥´õÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ½½·§ ¸¶¿ì½º ¸ðµ¨ ½ÃÀå¿¡¼­ÀÇ º¥´õ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ·§Æ® ¸¶¿ì½º ¸ðµ¨ ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ Áã-Á㠸𵨠½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× Ãßõ

Áã ¹× ¸¶¿ì½º ¸ðµ¨ ½ÃÀåÀÇ Àü·«Àû ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
    • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
    • Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®
      • Á¤Ä¡Àû
      • °æÁ¦Àû
      • »çȸÀû
      • ±â¼úÀû
      • ¹ýÀû
      • ȯ°æÀû

    Á¦6Àå Áã ¹× ¸¶¿ì½º ¸ðµ¨ ½ÃÀå ¸ðµ¨ À¯Çüº°

    • Á¶°ÇºÎ ¶Ç´Â ¼ö¼ú·Î º¯°æµÈ Áã
    • À¯ÀüÀÚ º¯Çü Áã
    • ÇÏÀ̺긮µå ¶Ç´Â ÄÜÁ¦´Ð Áã
    • ¸é¿ª °áÇÌ Áã
    • ±ÙÄ£ ±³¹èÇÑ Áã
    • ÀÌ°è ±³¹èÇÑ Áã

    Á¦7Àå Áã ¹× ¸¶¿ì½º ¸ðµ¨ ½ÃÀå : ±â¼úº°

    • Å©¸®½ºÆÛ
    • ¹è¾Æ Áٱ⠼¼Æ÷ ÁÖÀÔ
    • ¸¶ÀÌÅ©·Î ÀÎÁ§¼Ç
    • ÇÙÀ̽Ä

    Á¦8Àå Áã ¹× ¸¶¿ì½º ¸ðµ¨ ½ÃÀå : ¼­ºñ½ºº°

    • À°Á¾
    • µ¿°áº¸Á¸
    • À¯ÀüÀÚ °Ë»ç
    • ¸ðµ¨ÀÎ ¶óÀ̼±½º
    • °Ë¿ª
    • ÀçÆÄ»ý

    Á¦9Àå Áã ¹× ¸¶¿ì½º ¸ðµ¨ ½ÃÀå Ä¡·á ¿µ¿ªº°

    • ½ÉÇ÷°ü Áúȯ
    • ´ç´¢º´
    • ¸é¿ªÇаú ¿°Áõ
    • ½Å°æÇÐ
    • Á¾¾çÇÐ
    • µ¶¹°ÇÐ

    Á¦10Àå Áã ¹× ¸¶¿ì½º ¸ðµ¨ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

    • Çмú¿¬±¸±â°ü
    • °è¾à¿¬±¸±â°ü
    • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷

    Á¦11Àå ¾Æ¸Þ¸®Ä«ÀÇ Áã ¹× ¸¶¿ì½º ¸ðµ¨ ½ÃÀå

    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
    • ¹Ì±¹

    Á¦12Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Áã ¹× ¸¶¿ì½º ¸ðµ¨ ½ÃÀå

    • È£ÁÖ
    • Áß±¹
    • Àεµ
    • Àεµ³×½Ã¾Æ
    • ÀϺ»
    • ¸»·¹À̽þÆ
    • Çʸ®ÇÉ
    • ½Ì°¡Æ÷¸£
    • Çѱ¹
    • ´ë¸¸
    • ű¹
    • º£Æ®³²

    Á¦13Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Áã ¹× ¸¶¿ì½º ¸ðµ¨ ½ÃÀå

    • µ§¸¶Å©
    • ÀÌÁýÆ®
    • Çɶõµå
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • À̽º¶ó¿¤
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
    • ³ªÀÌÁö¸®¾Æ
    • ³ë¸£¿þÀÌ
    • Æú¶õµå
    • īŸ¸£
    • ·¯½Ã¾Æ
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ½ºÆäÀÎ
    • ½º¿þµ§
    • ½ºÀ§½º
    • ÅÍŰ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ¿µ±¹

    Á¦14Àå °æÀï ±¸µµ

    • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023
    • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
    • °æÀï ½Ã³ª¸®¿À ºÐ¼®
    • Àü·« ºÐ¼®°ú Á¦¾È

    ±â¾÷ ¸ñ·Ï

    • Allentown, Inc.
    • Aragen Life Sciences
    • Biocytogen
    • Biomere Biomedical Research Models, Inc.
    • Champions Oncology, Inc.
    • Charles River Laboratories International, Inc.
    • Crown Bioscience, Inc. by JSR Corp.
    • Cyagen US Inc.
    • Envigo by Inotiv, Inc.
    • GemPharmatech
    • GenOway SA
    • Harbour Biomed
    • Hera BioLabs
    • Ingenious Targeting Laboratory
    • Janvier Labs
    • Oncodesign Precision Medicine
    • Ozgene Pty Ltd.
    • PerkinElmer, Inc.
    • Pharmatest Services Oy
    • PolyGene AG
    • Taconic Biosciences, Inc.
    • The Jackson Laboratory
    • TransCure Bioservices
    • TransViragen, Inc.
    • Vivo Bio Tech Ltd.
    BJH 25.01.08

    The Rat & Mouse Model Market was valued at USD 2.27 billion in 2023, expected to reach USD 2.45 billion in 2024, and is projected to grow at a CAGR of 8.26%, to USD 3.97 billion by 2030.

    The rat and mouse model market serves a crucial role in biomedical research, offering a valuable insight into human disease mechanisms due to genetic and biological similarities between these rodents and humans. These models are essential for studying disease progression, drug interactions, and genetic expressions, thus a necessity in preclinical trials for pharmaceuticals and biotechnology industries. The application scope spans across oncology, cardiology, neuroscience, immunology, and genetic research, with end-users including research institutions, pharmaceutical companies, and contract research organizations. Currently, market growth is propelled by advancements in genetic engineering technologies, rising R&D investments, and an increasing prevalence of chronic diseases necessitating innovative therapeutics. Opportunities lie in personalized medicine, where customized mouse models can accelerate the development of targeted therapies. Additionally, the rise of CRISPR-Cas9 technology and expanded use of humanized mouse models through genetic modification broaden research capabilities, offering lucrative growth avenues. However, market expansion is constrained by ethical concerns regarding animal testing, regulatory challenges, and the transition towards alternative in vitro and in silico models. The complexity and cost associated with maintaining live animal colonies are also significant limitations. To capitalize on these opportunities, stakeholders should focus on integrating AI and machine learning to enhance data analysis efficacy from animal studies. Developing robust in vitro simulation techniques can complement and potentially replace traditional animal models, ensuring alignment with changing regulatory and ethical standards. Innovation should also focus on refining genetic manipulation procedures to improve model accuracy and relevance. While currently benefitting from a robust demand outlook, the rat and mouse model market faces a dynamic future, driven by technological advancements and shifting ethical perspectives, demanding adaptive strategies from players in the sector. Through continuous innovation and strategic adaptation, the market promises significant growth potential.

    KEY MARKET STATISTICS
    Base Year [2023] USD 2.27 billion
    Estimated Year [2024] USD 2.45 billion
    Forecast Year [2030] USD 3.97 billion
    CAGR (%) 8.26%

    Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Rat & Mouse Model Market

    The Rat & Mouse Model Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

    • Market Drivers
      • Significant demand for genetically modified models to validate therapeutic targets
      • Rising expenditures in R&D activities in the pharmaceutical and biotechnology sector
      • Surge in demand for personalized medicine
    • Market Restraints
      • Ethical concerns and limitation of rat & mouse model
    • Market Opportunities
      • Inclination towards humanized rat & mouse model
      • Growing therapeutic research areas
    • Market Challenges
      • Presence of alternative testing methods

    Porter's Five Forces: A Strategic Tool for Navigating the Rat & Mouse Model Market

    Porter's five forces framework is a critical tool for understanding the competitive landscape of the Rat & Mouse Model Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

    PESTLE Analysis: Navigating External Influences in the Rat & Mouse Model Market

    External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Rat & Mouse Model Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

    Market Share Analysis: Understanding the Competitive Landscape in the Rat & Mouse Model Market

    A detailed market share analysis in the Rat & Mouse Model Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

    FPNV Positioning Matrix: Evaluating Vendors' Performance in the Rat & Mouse Model Market

    The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Rat & Mouse Model Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

    Strategy Analysis & Recommendation: Charting a Path to Success in the Rat & Mouse Model Market

    A strategic analysis of the Rat & Mouse Model Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

    Key Company Profiles

    The report delves into recent significant developments in the Rat & Mouse Model Market, highlighting leading vendors and their innovative profiles. These include Allentown, Inc., Aragen Life Sciences, Biocytogen, Biomere Biomedical Research Models, Inc., Champions Oncology, Inc., Charles River Laboratories International, Inc., Crown Bioscience, Inc. by JSR Corp., Cyagen US Inc., Envigo by Inotiv, Inc., GemPharmatech, GenOway S.A., Harbour Biomed, Hera BioLabs, Ingenious Targeting Laboratory, Janvier Labs, Oncodesign Precision Medicine, Ozgene Pty Ltd., PerkinElmer, Inc., Pharmatest Services Oy, PolyGene AG, Taconic Biosciences, Inc., The Jackson Laboratory, TransCure Bioservices, TransViragen, Inc., and Vivo Bio Tech Ltd..

    Market Segmentation & Coverage

    This research report categorizes the Rat & Mouse Model Market to forecast the revenues and analyze trends in each of the following sub-markets:

    • Based on Model Type, market is studied across Conditioned or Surgically Modified Rats, Genetically Modified Rats, Hybrid or Congenic Rats, Immunodeficient Rats, Inbred Rats, and Outbred Rats.
    • Based on Technology, market is studied across CRISPR, Embryonic Stem Cell Injection, Microinjection, and Nuclear Transfer.
    • Based on Service, market is studied across Breeding, Cryopreservation, Genetic Testing, Model-in-Licensing, Quarantine, and Rederivation.
    • Based on Therapeutic Area, market is studied across Cardiovascular Disease, Diabetes, Immunology & Inflammation, Neurology, Oncology, and Toxicology.
    • Based on End-User, market is studied across Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies.
    • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

    The report offers a comprehensive analysis of the market, covering key focus areas:

    1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

    2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

    3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

    4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

    5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

    The report also answers critical questions to aid stakeholders in making informed decisions:

    1. What is the current market size, and what is the forecasted growth?

    2. Which products, segments, and regions offer the best investment opportunities?

    3. What are the key technology trends and regulatory influences shaping the market?

    4. How do leading vendors rank in terms of market share and competitive positioning?

    5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

    Table of Contents

    1. Preface

    • 1.1. Objectives of the Study
    • 1.2. Market Segmentation & Coverage
    • 1.3. Years Considered for the Study
    • 1.4. Currency & Pricing
    • 1.5. Language
    • 1.6. Stakeholders

    2. Research Methodology

    • 2.1. Define: Research Objective
    • 2.2. Determine: Research Design
    • 2.3. Prepare: Research Instrument
    • 2.4. Collect: Data Source
    • 2.5. Analyze: Data Interpretation
    • 2.6. Formulate: Data Verification
    • 2.7. Publish: Research Report
    • 2.8. Repeat: Report Update

    3. Executive Summary

    4. Market Overview

    5. Market Insights

    • 5.1. Market Dynamics
      • 5.1.1. Drivers
        • 5.1.1.1. Significant demand for genetically modified models to validate therapeutic targets
        • 5.1.1.2. Rising expenditures in R&D activities in the pharmaceutical and biotechnology sector
        • 5.1.1.3. Surge in demand for personalized medicine
      • 5.1.2. Restraints
        • 5.1.2.1. Ethical concerns and limitation of rat & mouse model
      • 5.1.3. Opportunities
        • 5.1.3.1. Inclination towards humanized rat & mouse model
        • 5.1.3.2. Growing therapeutic research areas
      • 5.1.4. Challenges
        • 5.1.4.1. Presence of alternative testing methods
    • 5.2. Market Segmentation Analysis
      • 5.2.1. Model Type: Significant critical insights provided by genetically modified rats into genetic functions and pathogenesis of genetic diseases
      • 5.2.2. Service: Expanding usage of rat and mouse models for breeding services due to the necessity to produce specific genetic backgrounds
    • 5.3. Porter's Five Forces Analysis
      • 5.3.1. Threat of New Entrants
      • 5.3.2. Threat of Substitutes
      • 5.3.3. Bargaining Power of Customers
      • 5.3.4. Bargaining Power of Suppliers
      • 5.3.5. Industry Rivalry
    • 5.4. PESTLE Analysis
      • 5.4.1. Political
      • 5.4.2. Economic
      • 5.4.3. Social
      • 5.4.4. Technological
      • 5.4.5. Legal
      • 5.4.6. Environmental

    6. Rat & Mouse Model Market, by Model Type

    • 6.1. Introduction
    • 6.2. Conditioned or Surgically Modified Rats
    • 6.3. Genetically Modified Rats
    • 6.4. Hybrid or Congenic Rats
    • 6.5. Immunodeficient Rats
    • 6.6. Inbred Rats
    • 6.7. Outbred Rats

    7. Rat & Mouse Model Market, by Technology

    • 7.1. Introduction
    • 7.2. CRISPR
    • 7.3. Embryonic Stem Cell Injection
    • 7.4. Microinjection
    • 7.5. Nuclear Transfer

    8. Rat & Mouse Model Market, by Service

    • 8.1. Introduction
    • 8.2. Breeding
    • 8.3. Cryopreservation
    • 8.4. Genetic Testing
    • 8.5. Model-in-Licensing
    • 8.6. Quarantine
    • 8.7. Rederivation

    9. Rat & Mouse Model Market, by Therapeutic Area

    • 9.1. Introduction
    • 9.2. Cardiovascular Disease
    • 9.3. Diabetes
    • 9.4. Immunology & Inflammation
    • 9.5. Neurology
    • 9.6. Oncology
    • 9.7. Toxicology

    10. Rat & Mouse Model Market, by End-User

    • 10.1. Introduction
    • 10.2. Academic & Research Institutes
    • 10.3. Contract Research Organizations
    • 10.4. Pharmaceutical & Biotechnology Companies

    11. Americas Rat & Mouse Model Market

    • 11.1. Introduction
    • 11.2. Argentina
    • 11.3. Brazil
    • 11.4. Canada
    • 11.5. Mexico
    • 11.6. United States

    12. Asia-Pacific Rat & Mouse Model Market

    • 12.1. Introduction
    • 12.2. Australia
    • 12.3. China
    • 12.4. India
    • 12.5. Indonesia
    • 12.6. Japan
    • 12.7. Malaysia
    • 12.8. Philippines
    • 12.9. Singapore
    • 12.10. South Korea
    • 12.11. Taiwan
    • 12.12. Thailand
    • 12.13. Vietnam

    13. Europe, Middle East & Africa Rat & Mouse Model Market

    • 13.1. Introduction
    • 13.2. Denmark
    • 13.3. Egypt
    • 13.4. Finland
    • 13.5. France
    • 13.6. Germany
    • 13.7. Israel
    • 13.8. Italy
    • 13.9. Netherlands
    • 13.10. Nigeria
    • 13.11. Norway
    • 13.12. Poland
    • 13.13. Qatar
    • 13.14. Russia
    • 13.15. Saudi Arabia
    • 13.16. South Africa
    • 13.17. Spain
    • 13.18. Sweden
    • 13.19. Switzerland
    • 13.20. Turkey
    • 13.21. United Arab Emirates
    • 13.22. United Kingdom

    14. Competitive Landscape

    • 14.1. Market Share Analysis, 2023
    • 14.2. FPNV Positioning Matrix, 2023
    • 14.3. Competitive Scenario Analysis
      • 14.3.1. Enhancing Preclinical Research through Advanced Genetically Modified Mouse Models by Charles River Laboratories
      • 14.3.2. Innovative Mouse Model Paves Way for New Therapies in Chronic Lymphocytic Leukaemia and Richter Transformation
      • 14.3.3. Pioneering a Mouse Model to Elucidate the Role of IL-6 in Frailty and Aging
    • 14.4. Strategy Analysis & Recommendation

    Companies Mentioned

    • 1. Allentown, Inc.
    • 2. Aragen Life Sciences
    • 3. Biocytogen
    • 4. Biomere Biomedical Research Models, Inc.
    • 5. Champions Oncology, Inc.
    • 6. Charles River Laboratories International, Inc.
    • 7. Crown Bioscience, Inc. by JSR Corp.
    • 8. Cyagen US Inc.
    • 9. Envigo by Inotiv, Inc.
    • 10. GemPharmatech
    • 11. GenOway S.A.
    • 12. Harbour Biomed
    • 13. Hera BioLabs
    • 14. Ingenious Targeting Laboratory
    • 15. Janvier Labs
    • 16. Oncodesign Precision Medicine
    • 17. Ozgene Pty Ltd.
    • 18. PerkinElmer, Inc.
    • 19. Pharmatest Services Oy
    • 20. PolyGene AG
    • 21. Taconic Biosciences, Inc.
    • 22. The Jackson Laboratory
    • 23. TransCure Bioservices
    • 24. TransViragen, Inc.
    • 25. Vivo Bio Tech Ltd.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦